3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
2
Withdrawn
1
Unknown
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
CNS
1
Breast
1
Conditions
Prostatic Neoplasms
3
Brain Neoplasms
2
Oligodendroglioma
1
Neoplastic Cells, Circulating
1
Neoplasm Metastasis
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Castrate-resistant Metastatic Prostate Cancer
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Astrocytoma
1
Interventions
Paclitaxel
28
Trastuzumab
22
Cyclophosphamide
21
Doxorubicin
14
Docetaxel
14
Carboplatin
11
exemestane
10
Radiotherapy
10
Letrozole
10
Capecitabine
10
pembrolizumab
8
Lapatinib
8
Fulvestrant
8
Neoadjuvant Therapy
6
Goserelin
6
Bevacizumab
6
Anastrozole
6
pertuzumab
5
palbociclib
5
eribulin
5
abemaciclib
5
Therapeutics
5
Magnetic Resonance Spectroscopy
5
Epirubicin
5
Chemotherapy, Adjuvant
5
Aromatase Inhibitors
5
tucatinib
4
Vinorelbine
4
Taxes
4
Tamoxifen
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Breast Neoplasms
×
cabazitaxel
×
Clear all
NCT01913067
2014-07-24
CRANIAL
Jules Bordet Institute
Phase 2
Withdrawn